Panel’s Recommendations People with HIV who are eligible for solid organ transplant (SOT) or hematopoietic cell transplant (HCT) should have equitable access to transplant (AII). People with HIV should be managed by a multidisciplinary team before, during, and after transplant (AIII). Transplant candidates with HIV should be up-to-date on their vaccination schedule (AIII). Antiretroviral Drug …
AU Comment: Transgender People with HIV in Australia. The barriers transgender people face engaging in care are universal and result from stigma, structural barriers and previous negative experiences of health care. These barriers may impact positive health outcomes such as viral suppression. Although accurate data regarding the number of TGD people in Australia is lacking, …
AU Comment: HPV Screening in women living with HIV In Australia, the National Cervical Screening Program (NCSP) guidelines recommend to the general population that cytological screening is replaced with 5 yearly HPV testing, with reflex liquid-based cytology and genotyping for positive samples. HIV-positive women have a higher incidence of cervical cancer and HPV-associated precancerous changes, …
This section has information on Management of the Treatment-Experienced Patient. Please click on the below links or follow the table of contents to access the information you are looking for. Virologic Failure Optimizing ART in the Setting of Virologic Suppression Poor CD4 Cell Recovery Discontinuation or Interruption of ARV
AU Comment: Australian Special Access Scheme for ARV treatments In heavily treatment-experienced patients, where treatment options are limited by drug resistance, toxicities or other issues, enrolment in a clinical trial of a new antiretroviral agent (if available), or use of an agent not yet TGA-approved for marketing but available through the Special Access Scheme, can …
AU Comment: Poor CD4 cell recovery and persistent inflammation despite viral suppression Current DHHS recommendations are suitable for implementation in Australia, including the following points: In individuals with viral suppression, adding ARV drugs or switching ARV drug classes does not consistently improve CD4 cell recovery or reduce all relevant markers of immune activation and is not …
Panel’s Recommendations for Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression Key Considerations and Panel’s Recommendations Advances in antiretroviral (ARV) treatment and a better understanding of HIV drug resistance have made it possible to consider switching a person with HIV from an effective ARV regimen to an alternative ARV regimen in some situations The …
Optimising ART in the Setting of Virologic Suppression Read More »
AU Comment: Ibalizumab (IBA) Ibalizumab (IBA) a monoclonal antibody that is NOT PBS listed in Australia. Discontinuation or interruption of antiretroviral therapy (ART) may result in viral rebound, immune decompensation, and/or clinical progression.1-5 Thus, discontinuation or planned interruption of ART is not recommended outside the context of a clinical trial (AI). However, unplanned interruption of ART may …
This section has information on What to Start. Please click on the below links or follow the table of contents to access the information you are looking for. Initial Combination ARV Regimens for People with HIV Nucleoside Reverse Transcriptase Inhibitor Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens Other ARV Regimens ARV Components or Regimens Not Recommended as …
AU Comment: CAB-LA in Australia Long-acting cabotegravir (CAB-LA) for PrEP was TGA approved in 2022 but as of June 2024, the process for listing this medication on the PBS has ceased. However, some patients may have accessed CAB-LA as PrEP while overseas. Clinicians should ensure that integrase genotypic resistance testing is requested to exclude integrase …
Initial Combination ARV Regimens for People with HIV Read More »